Discover the power of real-time signals plus AI
Every contract, funding round, exec hire, and M&A move on SUTRO BIOPHARMA INC — with verified, ICP-scored contact reveals (email + mobile) on demand.
Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.
Sutro Biopharma Inc. and Boehringer Ingelheim BioXcellence™ Partnership: Scaling Up Cell-Free Technology for Commercial Production
Contract Type
partnership
San FranciscoBiotechnologyDescription
Sutro Biopharma Inc. and Boehringer Ingelheim BioXcellence announced the successful application of Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin, a Tubulin FRα-targeting antibody-drug conjugate (ADC) designed to treat ovarian cancer and other FRα expressing cancers. This marked an industry milestone in large-scale GMP production at Boehringer’s manufacturing facility in Vienna, Austria.
Related People
Sign in to view contact details